Recent advance in targeted therapies for myasthenia gravis
10.3760/cma.j.cn115354-20230919-00129
- VernacularTitle:靶向生物制剂治疗重症肌无力的研究进展
- Author:
Luya JIN
1
;
Wei WANG
;
Shuang LI
;
Wenyu LI
Author Information
1. 浙江大学医学院附属邵逸夫医院神经内科，杭州 310016
- Keywords:
Myasthenia gravis;
Complement inhibitor;
B lymphocyte;
Monoclonal antibody;
Targeted therapy
- From:
Chinese Journal of Neuromedicine
2024;23(3):310-317
- CountryChina
- Language:Chinese
-
Abstract:
Myasthenia gravis (MG) is an autoimmune disease of the nervous system mediated by autoimmune antibodies, dependent on T cells and involved in multiple complement. Recent years, targeted biologics have shown advantages in a number of clinical studies of myasthenia gravis. This review focuses on targeted therapy on B cells, complement, neonatal fragment crystal receptor (FcRn) and cytokine monoclonal antibodies, as well as on the latest research progress of chimeric antigen receptor T cells (CAR-T) or chimeric autoantibody receptor T cells (CAAR-T) in MG therapy, in order to provide the latest drug information for clinicians.
